MBI gears up for Phase II trials of FSO69:
This article was originally published in Clinica
Executive Summary
Molecular Biosystems (US) plans to begin Phase II trials of its organ perfusion ultrasound contrast agent, FSO69, in the autumn following the successful completion of Phase I trials. Left ventricular border enhancement and myocardial perfusion were observed in all subjects in the initial trial, says MBI. Safety of the second generation agent has been demonstrated, says chairman and CEO Kenneth Widder. "Future clinical studies will be performed to verify efficacy in the liver and kidneys."
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.